Low-bitterness soluble composition capable of quickly and efficiently dispelling effects of alcohol, dispelling effects of alcohol, protecting liver or preventing drunkenness as well as preparation method and application of low-bitterness soluble composition

By assembling dihydromycein with cyclodextrin and phospholipids to form an inclusion body, the problem of dihydromycein's bitter taste and low bioavailability is solved, and its application in food and sobering effect is improved.

CN118985909APending Publication Date: 2024-11-22NANCHANG UNIV +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411115150.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-14
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The prior art is difficult to effectively solve the problems of bitter taste and low bioavailability of dihydrobaumin, which limits its application in food and health foods.

Method used

By assembling dihydromycetin with cyclodextrin and phospholipids or phospholipids, loading dihydromycetin with hydrophobic chamber of cyclodextrin, and improving its stability through the lipid vesicle structure of phospholipids or phospholipids and load, significantly suppressing bitter taste.

Benefits of technology

It improves the water solubility and bioavailability of dihydromycein, significantly reduces bitter taste, and achieves its widespread application and rapid sobering effect in food and health foods.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118985909A_ABST
    Figure CN118985909A_ABST
Patent Text Reader

Abstract

The invention discloses a low-bitterness soluble composition capable of quickly and efficiently dispelling the effects of alcohol, dispelling the effects of alcohol, protecting the liver or preventing drunkenness as well as a preparation method and application of the low-bitterness soluble composition, and relates to the technical field of food and health food industries including functional food. The low-bitterness soluble composition comprises dihydromyricetin, cyclodextrin and phospholipid or phospholipid-like in a weight ratio of (10-30): (20-80): (5-400). The dihydromyricetin is assembled in a hydrophobic cavity of the cyclodextrin, and the cyclodextrin containing the dihydromyricetin is loaded in the phospholipid or the phospholipid-like substance. The low-bitterness soluble composition provided by the invention is obvious in bitterness inhibition effect, high in sobering efficiency and quick in effect, and has a good application prospect in preparation of sobering, hangover alleviating, liver protection or drunkenness prevention products. The invention further provides a preparation method of the low-bitterness soluble composition. The method is high in production efficiency and good in stability.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of food and health food industry including functional food, and in particular to a low-bitterness soluble composition for rapid and efficient sobering up, hangover resolution, liver protection or anti-drunkenness, a preparation method and application thereof. Background Art

[0002] At present, drinking has become an indispensable part of people's life, work and social life, which makes drunkenness very common. Due to the different sensitivity of nerves to ethanol, gastrointestinal absorption capacity and liver metabolism and processing capacity, the human body's tolerance to ethanol varies greatly. Excessive drinking can damage the gastrointestinal tract, liver, nerves, cardiovascular and cerebrovascular organs, and can lead to mental disorders, gastric ulcers, fatty liver, alcoholic hepatitis and cirrhosis. Experts point out that 58% of liver cancer is caused by drinking. Long-term drinking or excessive drinking, especially drinking strong alcohol, will cause liver cells to repeatedly undergo fatty degeneration, necrosis and regeneration, leading to cirrhosis and eventually transforming into liver cancer. The proportion of liver cirrhosis transforming into liver cancer is as high as 70%.

[0003] With the improvement of living standards, people's self-care awareness has been significantly enhanced, and there is a strong demand for alcohol sobering and self-care products after drinking. But at present, people use alcohol sobering medicine to sober up after drinking, and by promoting ethanol metabolism, people are awakened from drunkenness as soon as possible, and the research on anti-drunkenness is less, and the reaction power and self-control of drunken people will decrease, and the cerebral cortex will be excited, and irrational and even dangerous things will be done, which is avoided by drinkers. And the alcohol sobering medicine at home is mostly Chinese medicine compound, and Chinese medicine compound has complex ingredients, and the specific components that play a role are difficult to be clear and the effective dose is difficult to control. Therefore, it is very promising to develop a brand-new functional food with high safety and good effect to sober up quickly in this area.

[0004] Dihydromyricetin (DMY), also known as ampelopsin, ampelopsis, dihydromyricetin, dihydromyricetin, etc., is from Ampelopsis grossedentata (Hand-Mazz) WTWan, belonging to the family Vitaceae, genus Ampelopsis, also known as vine tea, longevity vine, etc., and its main active ingredient is flavonoids. Such substances have many unique effects such as scavenging free radicals, anti-oxidation, anti-thrombosis, anti-tumor, and anti-inflammatory; and dihydromyricetin is a relatively special flavonoid. In addition to the general characteristics of flavonoids, it also has the effects of relieving alcohol poisoning, preventing alcoholic liver and fatty liver, inhibiting liver cell deterioration, and reducing the incidence of liver cancer. It also has a protective effect on liver damage caused by carbon tetrachloride, galactosamine, alcohols and other hepatotoxins.

[0005] In addition, dihydromyricetin can convert ethanol metabolism into acetaldehyde and accelerate decomposition, converting it into non-toxic and harmless substances, reducing damage to liver cells. Dihydromyricetin has a wide range of biological activities, scavenging free radicals, anti-oxidation, anti-thrombosis, anti-tumor, anti-inflammatory and other unique effects. Dihydromyricetin takes effect quickly and lasts for a long time, and there is no report on the toxicity of dihydromyricetin so far. It can be seen that dihydromyricetin is a good product for protecting the liver and sobering up. However, dihydromyricetin tastes bitter and has poor water solubility. The solubility of dihydromyricetin in acidic and neutral water at 25°C in the aqueous phase is about 0.02%; the molecular structure is unstable, and the multiple phenolic hydroxyl groups in the molecular structure of dihydromyricetin determine that dihydromyricetin has stronger pharmacological activity than other polyphenol compounds, but because the phenolic hydroxyl groups are extremely unstable, the stability of dihydromyricetin is extremely poor, especially in aqueous solution, and it is easily oxidized; the oral bioavailability is extremely low; therefore, the application of dihydromyricetin in clinical practice and in the food industry such as beverages and dietary agents is severely limited; therefore, it is very necessary to further explore a new economical and effective dihydromyricetin product.

[0006] Dihydromyricetin has a very low solubility in acidic and neutral water, is easily soluble in organic reagents, and is very easily degraded under alkaline conditions (pH>7.0), which limits its application in food preparations. Cyclodextrin (CD) can usually be used to increase drug solubility, but the solubility of some cyclodextrins in water is also very limited, such as the solubility of β-cyclodextrin in water is only 1.85%. Therefore, when preparing dihydromyricetin-cyclodextrin inclusion bodies, under normal conditions (such as stirring, ultrasound, etc.), the ability of dihydromyricetin to actively load into the cavity of cyclodextrin under saturated conditions is limited, and the dissolution of cyclodextrin itself is limited. Although the solubility of the raw material is improved, the overall load is difficult to increase, and the yield is low.

[0007] A large amount of flavors and sweeteners are usually added to food to cover up bad flavors such as bitterness. Although this method can alleviate, it cannot completely eliminate or completely cover up. Adding sweeteners can reduce the perception of bitterness and astringency by increasing the threshold of bitterness and astringency and deceiving the brain, and can also reduce the pungent feeling. CN109362928A improves the bitter taste caused by the reduction of water-soluble sugars in rattan tea during processing by adding natural stevioside after fixing. Although the structure that produces bad flavors can be eliminated by chemical synthesis or adding blockers, the addition of chemical substances in food is very limited, and many blockers do not comply with Chinese food regulations. Moreover, the processing cost of this method is high, and there is a risk of residual organic hazards in the processing process, so it still cannot be widely used. In addition, everyone has different perception and tolerance of taste, and the recognition of the masking effect is inconsistent, so adding sweeteners can only alleviate the flavor through seasoning, and cannot completely cover it up.

[0008] At present, the measures for sobering up and sobering up dihydromyricetin are usually supplemented with other Chinese medicinal ingredients or other active substances with physiological functions such as liver protection. CN114796197A prepares a capsule preparation by combining three substances, curcumin, dihydromyricetin and silymarin, and the proportion of dihydromyricetin is relatively low. The real sobering up effect may be curcumin and silymarin, and its biological absorption rate is difficult to verify. CN117582478A prepares an anti-intoxication preparation by decocting and filtering dihydromyricetin with various Chinese medicinal ingredients such as kudzu root, rhodiola rosea, and Poria cocos. However, it does not pay attention to the flavor of the preparation, retains the bitter taste of Chinese medicinal ingredients and dihydromyricetin itself, and is difficult to be accepted by drunkards. CN109528964A obtains a preparation for anti-intoxication, sobering up and protecting the liver by mixing rattan tea, galangal and Poria cocos, filtering, concentrating and drying. And it is proved by mouse experiments that it can effectively prevent acute poisoning caused by ethanol and has certain sobering up and anti-intoxication effects. In summary, at present, the stability and bioaccessibility of dihydromyricetin itself are difficult to be effectively guaranteed, and most of them are combined with traditional Chinese medicine ingredients and other active ingredients, and the ingredients that really play the role of hangover are unknown. At the same time, the bitter taste of traditional Chinese medicine and dihydromyricetin has not received attention and improvement, and it is difficult to be accepted by consumers, and even cannot be used in the food field.

[0009] In view of this, the present invention is proposed. Summary of the invention

[0010] The purpose of the present invention is to provide a low-bitter soluble composition for rapid and efficient sobering up, hangover resolution, liver protection or anti-drunkenness, a preparation method and its application to successfully mask or significantly reduce the bitter taste of dihydromyricetin and increase the drug loading of dihydromyricetin, thereby improving the sobering up effect.

[0011] The present invention is achieved in that:

[0012] In a first aspect, the present invention provides a low-bitter soluble composition, which comprises: dihydromyricetin, cyclodextrin and phospholipid or phospholipid-like, wherein the weight ratio is 10-30:20-80:5-400; dihydromyricetin is assembled in the hydrophobic cavity of cyclodextrin, and the phospholipid or phospholipid-like carries the cyclodextrin containing dihydromyricetin.

[0013] In a second aspect, the present invention further provides a method for preparing a low-bitter soluble composition, which comprises the following steps: preparing a low-bitter soluble composition by self-assembling dihydromyricetin, cyclodextrin, phospholipid or phospholipid-like substance.

[0014] In a third aspect, the present invention further provides the use of the low-bitter soluble composition or the low-bitter soluble composition prepared by the above-mentioned preparation method in the preparation of products for sobering up, sobering up, protecting the liver or preventing drunkenness.

[0015] In a fourth aspect, the present invention further provides a product for sobering up, sobering up, protecting the liver or preventing drunkenness, which comprises the above-mentioned low-bitterness soluble composition or the low-bitterness soluble composition prepared by the above-mentioned preparation method.

[0016] The present invention has the following beneficial effects:

[0017] The low bitter soluble composition provided by the present invention can load the hydrophobic dihydromyricetin molecule in the internal hydrophobic cavity through the special structure of hydrophobicity and hydrophilicity outside the cyclodextrin, and suppress the leakage of dihydromyricetin through intermolecular force, and improve its stability and dispersibility in water. The hydrophobic chamber of cyclodextrin helps to increase the loading amount of dihydromyricetin, and dihydromyricetin and cyclodextrin form inclusion bodies (i.e., dihydromyricetin is assembled in the hydrophobic cavity of cyclodextrin) and then enter the lipid vesicles of phospholipids or phospholipids, so that its bitterness is significantly suppressed. Thus, the water solubility of dihydromyricetin is improved, and the bitterness of dihydromyricetin is significantly suppressed, so that it can be widely used in food and health food more safely and efficiently.

[0018] The increase in the loading amount of dihydromyricetin in the low-bitter soluble composition helps to improve the absorption effect of dihydromyricetin in the subject's body, thereby achieving the effect of rapid sobering up.

[0019] The present invention also provides a method for preparing a low-bitter soluble composition, which has high production efficiency, and the produced low-bitter soluble composition has high sobering efficiency and quick effect, and has good application prospects in preparing products for sobering up, sobering up, protecting the liver or preventing drunkenness. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.

[0021] Figure 1 is a flow chart for preparing a low-bitter soluble composition;

[0022] Figure 2 The figure is a statistical result of the change of the concentration of dihydromyricetin in the blood of mice after intragastric administration of the low-bitterness soluble composition prepared in different embodiments over time;

[0023] Figure 3 This is a statistical result graph of the sobering time of mice after the "alcohol-infused mice" were gavaged with the low-bitterness soluble composition prepared in different embodiments.

[0024] Figure 4Schematic diagram of the dissolution of dihydromyricetin raw material and the low-bitterness soluble composition prepared in the best embodiment (Example 5) in double distilled water. DETAILED DESCRIPTION

[0025] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.

[0026] In a first aspect, the present invention provides a low-bitter soluble composition, which comprises: dihydromyricetin, cyclodextrin and phospholipid or phospholipid-like, wherein the weight ratio is 10-30:20-80:5-400; dihydromyricetin is assembled in the hydrophobic cavity of cyclodextrin, and the phospholipid or phospholipid-like carries the cyclodextrin containing dihydromyricetin.

[0027] Phospholipids or phospholipid-like molecules are self-assembled and form nanovesicles with a bilayer structure, and have a hydrophilic end and a long-chain alkyl hydrophobic end.

[0028] When the phospholipid or phospholipidoid is a phospholipid molecule, the phospholipid or phospholipidoid is a vesicle composed of a phospholipid bilayer, including hydrophilic and hydrophobic active ingredients. Compared with other carrier materials, the use of phospholipids as encapsulation materials has many advantages, such as low toxicity, high biocompatibility and high biodegradability, which helps to improve the efficacy (such as being used to encapsulate active ingredients) and bioavailability of nutritional supplements. When phospholipids are dispersed in water, multilayer vesicles are spontaneously formed, each layer is a phospholipid bilayer, and each layer is separated by a water phase. This vesicle with an internal closed aqueous phase can effectively protect the encapsulated active ingredients, mask their bad flavor, and improve their bioacceptability. The ability of phospholipids or phospholipidoids to improve the bioaccessibility of active substances is mainly due to the special interaction mechanism between them and cells. There may be two special adhesions between phospholipids or phospholipidoids and cells: specific adhesion and non-specific adhesion. Specific adhesion occurs when specific proteins on the phospholipid or phospholipidoid membrane bind to corresponding receptors on the cell surface. Phospholipids or phospholipid-like substances may bind to one or more receptors on the cell surface, and nonspecific adhesion occurs when the attractive force exceeds the repulsive force. These two types of adhesion result in high concentrations of phospholipids or phospholipid-like substances on the cell surface. Due to the active and passive transport of the cell itself, the contents wrapped in phospholipids or phospholipid-like substances leak out and are absorbed by the cell.

[0029] After a long period of large-scale experiments, the present invention unexpectedly found that the hydrophobic dihydromyricetin molecule can be loaded in the internal hydrophobic cavity by utilizing the special structure of hydrophobic and hydrophilic outside of cyclodextrin, and the leakage of dihydromyricetin is suppressed by intermolecular forces, and its stability and dispersibility are improved. The hydrophobic chamber of cyclodextrin helps to improve the loading capacity of dihydromyricetin, and dihydromyricetin and cyclodextrin form inclusion bodies (i.e., dihydromyricetin is assembled in the hydrophobic cavity of cyclodextrin) and then enter the lipid vesicles formed by phospholipids or phospholipids, so that its bitterness is significantly suppressed. Thus, the low-bitter soluble composition not only improves the water solubility of dihydromyricetin, but also significantly suppresses the bitterness of dihydromyricetin, and the active efficacy of dihydromyricetin can be improved under the support of phospholipids or phospholipids structures, so that it can be widely used in food and health food more safely and efficiently.

[0030] The special hydrophobic chamber in the composition cooperates with the stable phospholipid or phospholipid-like substance to increase the loading amount of dihydromyricetin, which is beneficial to the improvement of the absorption effect of dihydromyricetin in the body of the subject, thereby achieving the effect of rapid sobering up.

[0031] Under the above ratio conditions, the prepared low-bitterness soluble composition has lower bitterness.

[0032] In a preferred embodiment of the present invention, the weight ratio of dihydromyricetin, cyclodextrin, phospholipid or phospholipid is 10-30:20-80:5-160. When the weight ratio of dihydromyricetin, cyclodextrin, phospholipid or phospholipid is 10-30:20-80:80-160, due to the large amount of phospholipid or phospholipid added and relatively few water molecules, the fluidity of the prepared composition decreases, and the composition can be directly prepared as a solid product for use. The decrease in fluidity does not affect the use of the solid composition. When the weight ratio of dihydromyricetin, cyclodextrin, phospholipid or phospholipid is 10-30:20-80:5-80, the composition has a certain fluidity, and the composition can be prepared as a liquid, semi-solid or solid preparation.

[0033] In a preferred embodiment of the present invention, the weight ratio of dihydromyricetin, cyclodextrin, phospholipid or phospholipid is 10-30:20-80:5-120. For example, the weight ratio of dihydromyricetin, cyclodextrin, phospholipid or phospholipid is 10:30:5, 10:30:10, or 20:40:100, or 30:60:120, or 30:80:110, or 30:80:100, or 30:70:120, or 20:50:100.

[0034] In a preferred embodiment of the present invention, the weight ratio of dihydromyricetin, cyclodextrin, phospholipid or phospholipid-like is 10-30:20-80:5-80;

[0035] In a preferred embodiment of the present invention, the weight ratio of dihydromyricetin, cyclodextrin, phospholipid or phospholipid-like is 10-30:20-80:5-30;

[0036] In a preferred embodiment of the present invention, the weight ratio of dihydromyricetin, cyclodextrin, phospholipid or phospholipid-like is 10-30:20-80:10-30.

[0037] In a preferred embodiment of the present invention, the weight ratio of dihydromyricetin, cyclodextrin, phospholipid or phospholipid is 10-30:60-70:10-30. Under this ratio, the prepared composition has good fluidity and good bitterness elimination effect. In particular, when the weight ratio of dihydromyricetin, cyclodextrin, phospholipid or phospholipid is 10-30:60-70:10-20, the prepared composition has almost no bitter taste when taken in. For example, the weight ratio of dihydromyricetin, cyclodextrin, phospholipid or phospholipid is 10:60:10, or 15:60:10, or 18:65:20, or 20:70:10.

[0038] Phospholipid-like molecules refer to phospholipid-like molecules with amphiphilic properties similar to phospholipids, such as PCL-b-(PBrCL-g-PMPC) and other substances disclosed in patent CN202010717453.1.

[0039] In a preferred embodiment of the present invention, the lipid component in the phospholipid or phospholipid-like substance refers to: empty phospholipid or phospholipid-like substance containing or consisting of phosphatidylcholine and sphingomyelin, wherein the phosphatidylcholine is present in an amount of 15-98% (w / w).

[0040] In a preferred embodiment of the present invention, the phospholipids are selected from glycerophospholipids and sphingomyelin;

[0041] In a preferred embodiment of the present invention, the phospholipid is selected from any one of soybean lecithin, sunflower lecithin, DSPG (distearoylphosphatidylglycerol), DPPC, HSPC (hydrogenated soybean lecithin), DSPC (distearoylphosphatidylcholine) and EPC (egg yolk lecithin) or a combination of at least two thereof; such as a combination of HSPC and DSPC, a combination of HSPC and DSPC, a combination of HSPC and EPC, and the like. Other arbitrary combinations are not described in detail herein.

[0042] In a preferred embodiment of the present invention, when the phospholipid is lecithin, the content of phosphatidylcholine (PC) in the lecithin includes at least one of 15%, 30%, 35%, 50%, 60%, 70%, 80%, 90% and 98%;

[0043] The cyclodextrin is selected from at least one of α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin and hydroxypropyl-β-cyclodextrin;

[0044] In a preferred embodiment of the present invention, the cyclodextrin is selected from at least one of α-cyclodextrin, β-cyclodextrin and γ-cyclodextrin. β-cyclodextrin itself has low solubility in water, so the amount of phospholipids or phospholipid-like substances should not be too large. If the amount of phospholipids or phospholipid-like substances exceeds 10 times that of cyclodextrin, the phospholipids will swell and absorb water, which will reduce the overall moisture content of the composition and cause β-cyclodextrin to precipitate. γ-cyclodextrin has high solubility in water, and the above-mentioned precipitation does not occur.

[0045] In a preferred embodiment of the present invention, the low bitter soluble composition also includes water, and the solid mass ratio in the low bitter soluble composition is 10%-60%. Such as 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55% or 60%. Solid content refers to the total amount of water-insoluble substances in food, including soluble and insoluble solids. The present invention refers to the total content of dihydromyricetin, cyclodextrin, phospholipids or phospholipids.

[0046] In a second aspect, the present invention further provides a method for preparing a low-bitter soluble composition, which comprises the following steps: preparing a low-bitter soluble composition by self-assembling dihydromyricetin, cyclodextrin, phospholipid or phospholipid-like substance.

[0047] In a preferred embodiment of the present invention, dihydromyricetin and cyclodextrin are firstly prepared into a nano-solution, and then the nano-solution and phospholipid or phospholipid-like composition are prepared into a low-bitter soluble composition through self-assembly.

[0048] In a preferred embodiment of the present invention, the self-assembly method is one of the following methods: high-speed shear homogenization, high-pressure homogenization, high-speed oscillation or ultrasonic vibration.

[0049] In a preferred embodiment of the present invention, the self-assembly method is high-speed shear homogenization, and the conditions of high-speed shear homogenization are 8000-15000 r / min and the time is 10-30 min.

[0050] As an amphiphilic molecule, phospholipid or phospholipid-like molecule has the ability to spontaneously form vesicles in water, and the dihydromyricetin cyclodextrin inclusion body can be loaded into the interior of the vesicles to form a composition through the energy provided by high-speed shear dispersion.

[0051] In a preferred embodiment of the present invention, the nano-solution is prepared by high-speed grinding.

[0052] The use of high-speed nano-grinding technology can effectively increase the loading capacity. Nano-grinding mainly reduces the particle size to nanometer level by means of high-speed friction, collision and extrusion between the active ingredient particles (dihydromyricetin and cyclodextrin) and the grinding media. The grinding media are mainly composed of hard and dense materials, such as yttrium-stabilized zirconium oxide, alumina ceramics (or titanium), and polymer materials such as highly cross-linked polyethylene can also be used. The size of the beads can be from micrometer to millimeter.

[0053] Studies have shown that smaller-sized grinding beads can effectively increase the collision frequency between drug particles and beads, which helps to produce nanoparticles with smaller particle sizes. In the present invention, high-speed grinding can generate enough energy to passively load more dihydromyricetin molecules into the hydrophobic cavity of cyclodextrin, thereby greatly increasing the loading amount of dihydromyricetin in cyclodextrin. At the same time, high-speed nano-grinding does not rely on any organic reagents, and can also avoid the degradation of dihydromyricetin under harsh conditions. It is a very effective means to solve the difficult processing and utilization of dihydromyricetin. By high-speed nano-grinding, a high-content dihydromyricetin cyclodextrin inclusion body solution is obtained.

[0054] In a preferred embodiment of the present invention, the high-speed grinding conditions are: rotation speed 2000-3000 r / min, time 30-120 min, for example 2000-2500 r / min, or 2800-3000 r / min, time 30-60 min, or 60-90 min, or 50-120 min.

[0055] In a preferred embodiment of the present invention, the cyclodextrin aqueous solution is a cyclodextrin ethanol aqueous solution, wherein the mass percentage of ethanol is 5%-30%.

[0056] In a preferred embodiment of the present invention, the low-bitter soluble composition further comprises water, and the solid mass percentage of the low-bitter soluble composition is 10%-60%, such as 10%, 15%, 18%, 20%, 30%, 35%, 40%, 45%, 50%, 55% or 60%.

[0057] The pH value of the composition prepared by the invention is all less than 7, thus preventing dihydromyricetin from being easily degraded under alkaline conditions (pH>7.0).

[0058] In a third aspect, the present invention further provides a low-bitterness soluble composition or a use of the low-bitterness soluble composition prepared by the above-mentioned preparation method in preparing products for sobering up, sobering up, protecting the liver or preventing drunkenness.

[0059] Hangover sobering products are mainly used for short-term drunkenness or mild drunkenness, while alcohol detoxification products are more suitable for auxiliary sobering up or treating acute alcohol poisoning caused by long-term drinking or alcoholism.

[0060] In a preferred embodiment of the present invention, the product is a medicine, food or health product;

[0061] In a preferred embodiment of the present invention, when preparing a product having an auxiliary protective effect or a protective effect on the liver, the product is a medicine, a food or a health product;

[0062] In a preferred embodiment of the present invention, the dosage form of the health care product is capsule, tablet, powder, granule, pill or oral solution;

[0063] In a preferred embodiment of the present invention, the food is selected from beverages, meat, sausages, bread, candy, snacks, noodles, ice cream, dairy products, soups, electrolyte drinks, drinking water, chewing gum, capsules, tea and vitamin complexes; the electrolyte drinks include but are not limited to solid drinks. The chewing gum and candy can be chewable tablets.

[0064] In a preferred embodiment of the present invention, the dosage form of the drug is selected from: oral solution, tablet, powder, granule, capsule, enema or gastric lavage.

[0065] In a preferred embodiment of the present invention, the drug is an oral drug or an injectable drug.

[0066] In a preferred embodiment of the present invention, the drug further comprises a pharmaceutically acceptable carrier or auxiliary material, which is selected from at least one of a protective agent, an excipient, a binder, a disintegrant, a lubricant, a fragrance, a preservative, a stabilizer, a suspending agent, a dispersant and a diluent.

[0067] Examples include: excipients such as sucrose, starch, mannitol, sorbitol, lactose, glucose, cellulose, talc, calcium phosphate, calcium carbonate; binders such as cellulose, methylcellulose, hydroxypropyl cellulose, polypropyl pyrrolidone, gelatin, gum arabic, polyethylene glycol, sucrose, starch; disintegrants such as starch, hydrolyzed starch, carboxymethyl cellulose, carboxymethyl cellulose calcium salt, hydroxypropyl starch, sodium glycol starch, sodium bicarbonate, calcium phosphate, calcium citrate; lubricants such as magnesium stearate, talc, sodium lauryl sulfate; flavors such as citric acid, menthol, glycine , orange powder; preservatives, such as sodium benzoate, sodium bisulfite, parabens (such as methyl paraben, ethyl paraben, propyl paraben, butyl paraben); stabilizers, such as citric acid, sodium citrate, acetic acid and polycarboxylic acids from the titriplex series, such as diethylenetriaminepentaacetic acid (DTPA); suspending agents, such as methylcellulose, polyvinylpyrrolidone, aluminum stearate; dispersants; diluents, such as water, organic solvents; waxes, fats and oils, such as beeswax, cocoa butter; polyethylene glycol; white petrolatum, etc.

[0068] In a fourth aspect, the present invention further provides a product for sobering up, sobering up, protecting the liver or preventing drunkenness, which comprises the above-mentioned low-bitterness soluble composition or the low-bitterness soluble composition prepared by the above-mentioned preparation method. The form of the product includes but is not limited to solid, liquid or semi-solid.

[0069] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.

[0070] The bitterness evaluation of the present invention adopts a sensory evaluation experiment, and the specific method is as follows: 16 professional tasters are selected to form a sensory evaluation panel, all of whom have no taste disorders or relevant medical history that affects taste, and have undergone five basic taste screening training before conducting the taste evaluation of the test solution. The sensory evaluation ensures that the tasters participate voluntarily without any coercion, fully discloses the research requirements and risks, and obtains the written or oral consent of the participants. The bitterness standard uses a dihydromyricetin aqueous solution with the same concentration as the test sample. The bitterness of the test sample is evaluated using a scoring system. The full score is 10 points, 0-2 points for very obvious bitterness and strong difficulty in swallowing, 3-5 points for heavy bitterness, 6-7 points for weak bitterness, 8-10 points for weak bitterness and almost no bitterness. Before each taste test, the subjects rinsed their mouths with water and evaluated the taste of each sample (5 grams) by sipping and holding it in their mouths for a few seconds. Then they spit it out and rinse their mouths with distilled water before continuing to the next sample.

[0071] Example 1

[0072] This embodiment provides a low bitter soluble composition loaded with dihydromyricetin. Figure 1 As shown, the preparation method is as follows:

[0073] Dihydromyricetin: gamma cyclodextrin: pc50 soybean lecithin = 15g: 30g: 5g ratio, the solid content in pure water is 50%. First, cyclodextrin is dispersed in a food-grade ethanol aqueous solution, the ethanol mass ratio in the ethanol aqueous solution is 5%, and then dihydromyricetin and cyclodextrin ethanol aqueous solution (95°C) are put into a grinder for high-speed grinding, the grinding condition is 2800r / min, grinding for 60min, and vacuum rotary evaporation to remove ethanol to obtain a dihydromyricetin cyclodextrin inclusion body solution. Then, the dihydromyricetin cyclodextrin inclusion body solution and the phospholipid solution are dispersed at 12000 rpm for 15 minutes to obtain a dihydromyricetin cyclodextrin liposome composite material. The composite material loaded with dihydromyricetin finally obtained has a uniform texture, relatively poor fluidity, very obvious bitterness in the mouth, and difficult to swallow, but it is slightly improved compared to the bitterness of the dihydromyricetin raw material. The solid content of this ratio in water is 50%, and the fluidity is relatively poor. At the same time, the concentration of dihydromyricetin in water is relatively high, so the bitterness is more obvious. After being prepared into cyclodextrin phospholipids or phospholipid-like substances, the bitterness is lower than that of pure dihydromyricetin at the same concentration, but it still tastes obviously bitter.

[0074] Embodiment 2:

[0075] This embodiment provides a low-bitter soluble composition loaded with dihydromyricetin. The preparation method thereof is as follows:

[0076] Dihydromyricetin: gamma cyclodextrin: pc50 soybean lecithin = 20g: 60g: 20g ratio, the solid content in pure water is 40%. First, cyclodextrin is dispersed in a food-grade ethanol aqueous solution, the mass percentage of ethanol in the ethanol aqueous solution is 15%, and then dihydromyricetin and cyclodextrin ethanol aqueous solution (85°C) are put into a grinder for high-speed grinding, the grinding condition is 2800r / min, grinding for 60min, and ethanol is removed by vacuum rotary evaporation to obtain a dihydromyricetin cyclodextrin inclusion body solution. Then, the dihydromyricetin cyclodextrin inclusion body solution and the phospholipid solution are dispersed by 12000 rpm high-speed shearing for 15 minutes to obtain a dihydromyricetin cyclodextrin liposome composite material. The composite material loaded with dihydromyricetin finally obtained has a uniform texture, good fluidity, obvious bitterness in the mouth, and a strong bitter taste in the mouth after swallowing.

[0077] Example 3

[0078] This embodiment provides a low-bitter soluble composition loaded with dihydromyricetin. The preparation method thereof is as follows:

[0079] Dihydromyricetin, gamma cyclodextrin, and PC50 soybean lecithin are mixed in a ratio of 10g:60g:30g, and the solid content in pure water is 30%. First, cyclodextrin is dispersed in a food-grade ethanol aqueous solution, and the mass percentage of ethanol in the ethanol aqueous solution is 30%. Then, dihydromyricetin and cyclodextrin ethanol aqueous solution (85°C) are put into a grinder for high-speed grinding. The grinding conditions are 2800r / min, grinding for 60min, and ethanol is removed by vacuum rotary evaporation to obtain a dihydromyricetin cyclodextrin inclusion body solution. Then, the dihydromyricetin cyclodextrin inclusion body solution and the phospholipid solution are dispersed at 12000 rpm for 15 minutes to obtain a dihydromyricetin cyclodextrin liposome composite material. The composite material loaded with dihydromyricetin finally obtained has uniform texture, good fluidity, light bitterness in the mouth, and weak bitterness in the mouth after swallowing.

[0080] Embodiment 4:

[0081] This embodiment provides a low-bitter soluble composition loaded with dihydromyricetin. The preparation method thereof is as follows:

[0082] Dihydromyricetin, gamma cyclodextrin, and PC50 soybean lecithin are mixed in a ratio of 10g:70g:20g, and the solid content in pure water is 30%. First, cyclodextrin is dispersed in a food-grade ethanol aqueous solution, and the mass percentage of ethanol in the ethanol aqueous solution is 30%. Then, dihydromyricetin and cyclodextrin ethanol aqueous solution (85°C) are put into a grinder for high-speed grinding. The grinding condition is 3000r / min, and the grinding is 120min. The ethanol is removed by vacuum rotary evaporation to obtain a dihydromyricetin cyclodextrin inclusion body solution. Then, the dihydromyricetin cyclodextrin inclusion body solution and the phospholipid solution are dispersed by 8000 rpm high-speed shearing for 30 minutes to obtain a dihydromyricetin cyclodextrin liposome composite material. The composite material loaded with dihydromyricetin finally obtained has uniform texture, good fluidity, no bitter taste in the mouth, and almost no bitter taste in the mouth after swallowing.

[0083] Embodiment 5:

[0084] This embodiment provides a low-bitter soluble composition loaded with dihydromyricetin. The preparation method thereof is as follows:

[0085] Dihydromyricetin, gamma cyclodextrin, and PC50 soybean lecithin are mixed in a ratio of 10g:80g:10g, and the solid content in pure water is 30%. First, cyclodextrin is dispersed in a food-grade ethanol aqueous solution, and the mass percentage of ethanol in the ethanol aqueous solution is 30%. Then, dihydromyricetin and cyclodextrin ethanol aqueous solution (85°C) are put into a grinder for high-speed grinding. The grinding conditions are 3000r / min, grinding for 120min, and ethanol is removed by vacuum rotary evaporation to obtain a dihydromyricetin cyclodextrin inclusion body solution. Then, the dihydromyricetin cyclodextrin inclusion body solution and the phospholipid solution are dispersed by 8000 rpm high-speed shearing for 30 minutes to obtain a dihydromyricetin cyclodextrin liposome composite material. The composite material loaded with dihydromyricetin finally obtained has uniform texture, good fluidity, no bitter taste in the mouth, and almost no bitter taste in the mouth after swallowing.

[0086] The low bitterness soluble composition prepared in this example is dissolved in double distilled water. Figure 4 As shown, the actual dissolution picture of dihydromyricetin raw material in double distilled water is used as a control.

[0087] Example 6

[0088] This embodiment provides a low-bitter soluble composition loaded with dihydromyricetin, and its preparation method is the same as the method in Example 5, except that the ratio of raw materials is different. In this embodiment, dihydromyricetin, cyclodextrin (γ-CD), and phospholipid are set in a ratio of 1:10:50.

[0089] Example 7

[0090] This embodiment provides a low-bitter soluble composition loaded with dihydromyricetin, and its preparation method is the same as the method in Example 5, except that the ratio of raw materials is different. In this embodiment, dihydromyricetin, cyclodextrin (γ-CD), and phospholipid are set in a ratio of 1g:10g:100g.

[0091] Example 8

[0092] This embodiment provides a low-bitter soluble composition loaded with dihydromyricetin. The preparation method thereof is as follows:

[0093] Dihydromyricetin, gamma cyclodextrin, and PC50 soybean lecithin are mixed in a ratio of 10g:80g:10g, and the solid content in pure water is 30%. First, cyclodextrin is dispersed in a food-grade ethanol aqueous solution, the mass percentage of ethanol in the ethanol aqueous solution is 30%, and then dihydromyricetin and cyclodextrin ethanol aqueous solution are put into a grinder for high-speed grinding, the grinding condition is 2800r / min, grinding for 60min, and ethanol is removed by vacuum rotary evaporation to obtain a dihydromyricetin cyclodextrin inclusion body solution. Then, the dihydromyricetin cyclodextrin inclusion body solution and the phospholipid solution are dispersed by 12000 rpm high-speed shearing for 15 minutes to obtain a dihydromyricetin cyclodextrin liposome composite material. The composite material loaded with dihydromyricetin finally obtained has uniform texture, good fluidity, light bitterness in the mouth, and weak bitterness in the mouth after swallowing.

[0094] Comparative Example 1

[0095] In this comparative example, the dihydromyricetin raw material powder is directly used for comparative test.

[0096] The raw powder of dihydromyricetin is insoluble in water and is difficult to swallow. It has a strong and lingering bitter flavor when it first enters the mouth, has a poor hangover-relieving effect, and has a low blood drug concentration.

[0097] Comparative Example 2:

[0098] In this comparative example, dihydromyricetin and cyclodextrin are mixed in a ratio of 10:80, and the solid content in pure water is 27%. First, cyclodextrin is dispersed in a food-grade ethanol aqueous solution, and the mass percentage of ethanol in the ethanol aqueous solution is 30%. Then, dihydromyricetin and cyclodextrin ethanol aqueous solution are put into a grinder for high-speed grinding. The grinding condition is 3000r / min, and the grinding is 120min. The ethanol is removed by vacuum rotary evaporation to obtain a dihydromyricetin cyclodextrin inclusion body solution. The bitterness of the entrance is better than that of the raw material, but it is still bitter and astringent, and the blood medicine is better than the raw material.

[0099] Comparative Example 3

[0100] In this comparative example, dihydromyricetin and cyclodextrin (γ-CD) are mixed in a ratio of 1:10, and the solid content in pure water is 27%. Cyclodextrin is first dispersed in a food-grade ethanol aqueous solution, the mass percentage of ethanol in the ethanol aqueous solution is 30%, and then dihydromyricetin and cyclodextrin ethanol aqueous solution are put into a grinder for high-speed grinding, the grinding condition is 3000r / min, the grinding time is 120min, and the ethanol is removed by vacuum rotary evaporation to obtain a dihydromyricetin cyclodextrin inclusion body solution.

[0101] Comparative Example 4

[0102] In this comparative example, dihydromyricetin and cyclodextrin (β-CD) are mixed in a ratio of 1:10, and the solid content in pure water is 27%. Cyclodextrin is first dispersed in a food-grade ethanol aqueous solution, the mass percentage of ethanol in the ethanol aqueous solution is 30%, and then dihydromyricetin and cyclodextrin ethanol aqueous solution are put into a grinder for high-speed grinding, the grinding condition is 3000r / min, the grinding time is 120min, and the ethanol is removed by vacuum rotary evaporation to obtain a dihydromyricetin cyclodextrin inclusion body solution.

[0103] Comparative Example 5

[0104] In this comparative example, dihydromyricetin and cyclodextrin (α-CD) are mixed in a ratio of 1:10, and the solid content in pure water is 27%. Cyclodextrin is first dispersed in a food-grade ethanol aqueous solution, the mass percentage of ethanol in the ethanol aqueous solution is 30%, and then dihydromyricetin and cyclodextrin ethanol aqueous solution are put into a grinder for high-speed grinding, the grinding condition is 3000r / min, the grinding time is 120min, and the ethanol is removed by vacuum rotary evaporation to obtain a dihydromyricetin cyclodextrin inclusion body solution.

[0105] Comparative Example 6

[0106] In this comparative example, dihydromyricetin and cyclodextrin (γ-CD) are mixed in a ratio of 1:5, and the solid content in pure water is 27%. Cyclodextrin is first dispersed in a food-grade ethanol aqueous solution, the mass percentage of ethanol in the ethanol aqueous solution is 30%, and then dihydromyricetin and cyclodextrin ethanol aqueous solution are put into a grinder for high-speed grinding, the grinding condition is 3000r / min, the grinding time is 120min, and the ethanol is removed by vacuum rotary evaporation to obtain a dihydromyricetin cyclodextrin inclusion body solution.

[0107] Comparative Example 7

[0108] In this comparative example, dihydromyricetin and cyclodextrin (β-CD) are mixed in a ratio of 1:5, and the solid content in pure water is 27%. Cyclodextrin is first dispersed in a food-grade ethanol aqueous solution, the mass percentage of ethanol in the ethanol aqueous solution is 30%, and then dihydromyricetin and cyclodextrin ethanol aqueous solution are put into a grinder for high-speed grinding, the grinding condition is 3000r / min, the grinding time is 120min, and the ethanol is removed by vacuum rotary evaporation to obtain a dihydromyricetin cyclodextrin inclusion body solution.

[0109] Comparative Example 8

[0110] In this comparative example, dihydromyricetin and cyclodextrin (γ-CD) are mixed in a ratio of 1:20, and the solid content in pure water is 27%. First, cyclodextrin is dispersed in a food-grade ethanol aqueous solution, the mass percentage of ethanol in the ethanol aqueous solution is 30%, and then dihydromyricetin and cyclodextrin ethanol aqueous solution are put into a grinder for high-speed grinding, the grinding condition is 3000r / min, grinding for 120min, and ethanol is removed by vacuum rotary evaporation to obtain a dihydromyricetin cyclodextrin inclusion body solution. Then, a phospholipid of the same mass as cyclodextrin is added, and then the dihydromyricetin cyclodextrin inclusion body solution and the phospholipid solution are dispersed by 8000 rpm high-speed shearing for 30 minutes to obtain a dihydromyricetin cyclodextrin liposome composite material.

[0111] Comparative Example 9

[0112] In this comparative example, dihydromyricetin and cyclodextrin (γ-CD) are mixed in a ratio of 1:20, and the solid content in pure water is 27%. First, cyclodextrin is dispersed in a food-grade ethanol aqueous solution, the mass percentage of ethanol in the ethanol aqueous solution is 30%, and then dihydromyricetin and cyclodextrin ethanol aqueous solution are put into a grinder for high-speed grinding, the grinding condition is 3000r / min, grinding for 120min, and ethanol is removed by vacuum rotary evaporation to obtain a dihydromyricetin cyclodextrin inclusion body solution. Then phospholipids are added, the mass of phospholipids accounts for half of the mass of cyclodextrin, and then the dihydromyricetin cyclodextrin inclusion body solution and the phospholipid solution are dispersed by 8000 rpm high-speed shearing for 30 minutes to obtain a dihydromyricetin cyclodextrin liposome composite material.

[0113] Comparative Example 10

[0114] In this comparative example, dihydromyricetin and cyclodextrin (β-CD) are mixed in a ratio of 1:20, and the solid content in pure water is 27%. Cyclodextrin is first dispersed in a food-grade ethanol aqueous solution, the mass percentage of ethanol in the ethanol aqueous solution is 30%, and then dihydromyricetin and cyclodextrin ethanol aqueous solution are put into a grinder for high-speed grinding, the grinding condition is 3000r / min, the grinding time is 120min, and the ethanol is removed by vacuum rotary evaporation to obtain a dihydromyricetin cyclodextrin inclusion body solution.

[0115] Comparative Example 11

[0116] In this comparative example, dihydromyricetin and cyclodextrin (β-CD) are mixed in a ratio of 1:10, and the solid content in pure water is 27%. First, cyclodextrin is dispersed in a food-grade ethanol aqueous solution, the mass percentage of ethanol in the ethanol aqueous solution is 30%, and then dihydromyricetin and cyclodextrin ethanol aqueous solution are put into a grinder for high-speed grinding, the grinding condition is 3000r / min, grinding for 120min, and ethanol is removed by vacuum rotary evaporation to obtain a dihydromyricetin cyclodextrin inclusion body solution. Then phospholipids are added, the mass of phospholipids is 5 times the mass of cyclodextrin, and then the dihydromyricetin cyclodextrin inclusion body solution and the phospholipid solution are dispersed by 8000 rpm high-speed shearing for 30 minutes to obtain a dihydromyricetin cyclodextrin liposome composite material.

[0117] Comparative Example 12

[0118] In this comparative example, dihydromyricetin and cyclodextrin (β-CD) are mixed in a ratio of 1:10, and the solid content in pure water is 27%. First, cyclodextrin is dispersed in a food-grade ethanol aqueous solution, the mass percentage of ethanol in the ethanol aqueous solution is 30%, and then dihydromyricetin and cyclodextrin ethanol aqueous solution are put into a grinder for high-speed grinding, the grinding condition is 3000r / min, grinding for 120min, and ethanol is removed by vacuum rotary evaporation to obtain a dihydromyricetin cyclodextrin inclusion body solution. Then phospholipids are added, the mass of phospholipids is 10 times the mass of cyclodextrin, and then the dihydromyricetin cyclodextrin inclusion body solution and the phospholipid solution are dispersed by 8000 rpm high-speed shearing for 30 minutes to obtain a dihydromyricetin cyclodextrin liposome composite material.

[0119] Comparative Example 13

[0120] In this comparative example, dihydromyricetin and cyclodextrin (γ-CD) are mixed in a ratio of 1:10, and the solid content in pure water is 27%. First, cyclodextrin is dispersed in a food-grade ethanol aqueous solution, the mass percentage of ethanol in the ethanol aqueous solution is 30%, and then dihydromyricetin and cyclodextrin ethanol aqueous solution are put into a grinder for high-speed grinding, the grinding condition is 3000r / min, grinding for 120min, and ethanol is removed by vacuum rotary evaporation to obtain a dihydromyricetin cyclodextrin inclusion body solution. Then phospholipids are added, the mass of phospholipids is equal to the mass of cyclodextrin, and then the dihydromyricetin cyclodextrin inclusion body solution and the phospholipid solution are dispersed by 8000 rpm high-speed shearing for 30 minutes to obtain a dihydromyricetin cyclodextrin liposome composite material.

[0121] Experimental Example 1

[0122] The encapsulation efficiency, cyclodextrin precipitation and bitterness of the compositions prepared in Comparative Examples 1-12 and Examples 1-7 were tested respectively, and the results are shown in Table 1:

[0123]

[0124]

[0125] Experimental Example 2

[0126] Since the samples prepared in Examples 4-5 have no difference in appearance and taste, they all show good fluidity and no bitterness in the mouth, which is a suitable formula for taking. Therefore, the samples prepared under these two groups of formulas are selected to perform a mouse blood drug concentration determination experiment to determine the concentration of dihydromyricetin in the blood drug. The concentration value is proportional to the hangover effect. The specific experiment is as follows: Test the concentration of dihydromyricetin in mouse plasma. 12 ICR male mice were randomly divided into 3 groups, 4 in each group, and fasted for 12 hours before the experiment. Dihydromyricetin raw materials, samples of Example 4, samples of Example 5, and samples of Comparative Example 2 were dispersed in ultrapure water, and all gavage samples were prepared and used. Single feeding was used for bioavailability evaluation with 160 mg / kg dihydromyricetin. Blood was continuously collected at preset time points before and after the perfusion of each group of mice. Each collection point was collected from the mouse neck vein blood and placed in a prepared heparin sodium tube, and the blood was gently shaken to fully mix the anticoagulant. The blood samples were placed in an ice box, protected from light, and centrifuged in a refrigerated centrifuge (3000 rpm for 10 min) within 30 minutes after collection. The serum after centrifugation was transferred to a cryotube for subsequent testing. Figure 2 The results show that Example 5 has the highest blood drug concentration and the best hangover-relieving effect.

[0127] Experimental Example 3

[0128] Mouse sobering experiment: The experiment set 12 SPF male C57BL / 6J mice with a mass of 20±2g. The mice were adaptively fed for one week. The conditions of animal breeding were temperature: 22±2°C; relative humidity: 55%±5%; 12h of light per day; free access to food and water. 12 mice were randomly divided into 3 groups, 4 in each group. The dihydromyricetin raw material was evenly dispersed in DMSO solution, and the samples of Example 4, Example 5, and Comparative Example 2 were dispersed in ultrapure water. All gavage samples were prepared and used immediately. A single feeding of 160mg / kg dihydromyricetin was used to evaluate the sobering effect. The timing started immediately after the mice were gavaged with wine, and the "righting reflex test" was used to observe the behavior of the mice after drinking. When the mice walked swaying or slow, they were placed on their backs and timed. If the mouse lay on its back for more than 30s, it was considered that the righting reflex disappeared, and the disappearance time of the righting reflex (drunkenness latency) and the number of drunken mice were recorded. When the mouse can turn over twice within 60 seconds, it is considered that the righting reflex is restored, and the time it takes for the mouse to recover to this state (sobering time) is recorded. Figure 3 The results show that both Example 5 and Example 4 have good sobering effects.

[0129] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A low bitterness soluble composition, characterized in that It includes: The weight ratio of dihydromyricetin, cyclodextrin and phospholipid or phospholipid-like is 10-30:20-80:5-400; the dihydromyricetin is assembled in the hydrophobic cavity of cyclodextrin, and the phospholipid or phospholipid-like carries the cyclodextrin containing the dihydromyricetin.

2. The low bitterness soluble composition according to claim 1, characterized in that The weight ratio of dihydromyricetin, cyclodextrin, phospholipid or phospholipid-like is 10-30:20-80:5-160; Preferably, the weight ratio of dihydromyricetin, cyclodextrin, phospholipid or phospholipid-like is 10-30:20-80:5-120; Preferably, the weight ratio of dihydromyricetin, cyclodextrin, phospholipid or phospholipid-like is 10-30:20-80:5-80; Preferably, the weight ratio of dihydromyricetin, cyclodextrin, phospholipid or phospholipid-like is 10-30:20-80:5-30; Preferably, the weight ratio of dihydromyricetin, cyclodextrin, phospholipid or phospholipid-like is 10-30:20-80:5-30. Preferably, the weight ratio of dihydromyricetin, cyclodextrin, phospholipid or phospholipid-like is 10-30:60-70:5-30.

3. The low bitterness soluble composition according to claim 1, characterized in that The phospholipids are selected from glycerophospholipids and sphingomyelin; Preferably, the phospholipid is selected from any one or a combination of at least two of soybean lecithin, sunflower lecithin, DSPG, DPPC, HSPC, DSPC and EPC; Preferably, when the phospholipid is lecithin, the content of phosphatidylcholine (PC) in the lecithin includes at least one of 15%, 30%, 35%, 50%, 60%, 70%, 80%, 90% and 98%; The cyclodextrin is selected from at least one of α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin and hydroxypropyl-β-cyclodextrin; Preferably, the cyclodextrin is selected from at least one of α-cyclodextrin, β-cyclodextrin and γ-cyclodextrin; Preferably, the low-bitter soluble composition further comprises water, and the solid content in the low-bitter soluble composition accounts for 10%-60% by weight.

4. A method for preparing the low-bitter soluble composition according to any one of claims 1 to 3, characterized in that: The method comprises the following steps: preparing a low-bitter soluble composition by self-assembling dihydromyricetin, cyclodextrin, phospholipid or phospholipid-like composition.

5. The preparation method according to claim 4, characterized in that: Firstly, the dihydromyricetin and cyclodextrin are prepared into a nano solution, and then the nano solution and the phospholipid or phospholipid-like composition are prepared through self-assembly.

6. The preparation method according to claim 5, characterized in that: The self-assembly method is one of the following methods: high-speed shear homogenization, high-pressure homogenization, high-speed oscillation or ultrasonic vibration; Preferably, the self-assembly method is high-speed shear homogenization, and the conditions of the high-speed shear homogenization are 8000-15000 r / min and the time is 10-30 min.

7. The preparation method according to claim 5, characterized in that: The nano-solution is prepared by high-speed grinding; Preferably, the conditions for high-speed grinding are: rotation speed 2000-3000 r / min, time 30-120 min.

8. The preparation method according to claim 5, characterized in that: The cyclodextrin is a cyclodextrin aqueous solution; Preferably, the cyclodextrin aqueous solution is a cyclodextrin ethanol aqueous solution, wherein the mass percentage of ethanol is 5%-30%; Preferably, the low-bitter soluble composition further comprises water, and the solid content in the low-bitter soluble composition accounts for 10%-60% by weight.

9. Use of the low-bitter soluble composition according to any one of claims 1 to 3 or the low-bitter soluble composition prepared by the preparation method according to any one of claims 4 to 8 in preparing products for sobering up, sobering up, protecting the liver or preventing drunkenness; Preferably, the product is a medicine, food or health product; Preferably, when preparing a product having an auxiliary protective effect or a protective effect on the liver, the product is a medicine, a food or a health product; Preferably, the dosage form of the health product is capsule, tablet, powder, granule, pill or oral solution; Preferably, the food is selected from drinks, meat, sausages, bread, candy, snacks, noodles, ice cream, dairy products, soups, electrolyte drinks, drinking water, chewing gum, capsules, tea and vitamin complexes; Preferably, the dosage form of the drug is selected from: oral solution, tablet, powder, granule, capsule, enema or gastric gavage.

10. A product for sobering up, sobering up, protecting the liver or preventing drunkenness, characterized in that: The invention comprises the low-bitter soluble composition according to any one of claims 1 to 3 or the low-bitter soluble composition prepared by the preparation method according to any one of claims 4 to 8.